PUBLIC PHARMA FOR EUROPE

PUBLIC PHARMA FOR EUROPE has been a member of Linktree for 1 year and joined in September 2024. The social media accounts linked to from PUBLIC PHARMA FOR EUROPE are: Instagram, LinkedIn, Email, X, Mastodon. Besides social media accounts, publicpharmaforeurope has populated their site with La política del medicamento en la UE y su renuncia a la salud global - Public Pharma For Europe, Free trade agreement with Malaysia: Switzerland imperils the rights to food and health, Fearing Trump cuts, California Democrat proposes creating state’s own NIH, Dutch health minister backs Critical Medicines Act, says full implications being assessed, La ministra della Salute olandese sostiene il Critical Medicines Act e valuta le implicazioni complete della proposta, EAHP 2023 Shortage Survey Report, In Defense of Public Pharma at the University Medical Center Groningen: A Statement of Solidarity, Gesubsidieerd en superrijk: de farmaceutische industrie moet anders, Bussola della competitività: Una manna per il settore farmaceutico e un colpo per la salute pubblica?, Competitiveness Compass: A boon to pharma, a blow to public health?, Public Pharma: What It Is and Why It’s Important?, The Privatization of Societal Vaccinology in the Netherlands, Swedish medicines agency wants state-run pharma production to prevent shortages, Trends in Pharmaceutical Expenditure, Reclaiming medicines and health innovation for our health, Public Pharma for Europe: The case of CAR-T cell therapy, A European Salk Institute Could Ensure Accessible and Affordable Medicines, Notre proposition concrète d’un pôle public du médicament, What are countries doing to tackle worsening drug shortages, The European Pharmaceutical Package Agreement: an insufficient step that preserves industry privileges and fails to guarantee equitable access to medicines, Making Access to Quality Healthcare a Top Priority for the EU, EU underfunds medicines while allocating billions to arms, Is Big Pharma’s pollution deregulation campaign fueling the next pandemic?, What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing, Közgyógyszeripar: továbbra is hiányzó téma a mainstream akadémiában, Public Pharma: still a missing debate in mainstream academia, Technology transfer, intellectual property, and the fight for the soul of WHO, Medicine For All: The Case for a Public Option in the Pharmaceutical Industry, Transformative policies to realise universal access to medicines: Why we need knowledge commons and public options for pharmaceuticals to realise the right to health, European pharmaceutical research and development: Could public infrastructure overcome market failures?, Medical research without patents: It’s preferable, it’s profitable, and it’s practicable, 29 years without Jonas Salk: against the normalization of the absurd, New $55 Insulin Pens Mark Step in California’s Fight Against Insulin Price Gouging, ‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers, A história dos insurgentes Médicos para o Povo, Farmacêuticas Públicas: um debate ainda ausente na academia hegemónica, Knowledge Hub, The UK must defend drug price controls, Bridging the Gap: securing access to essential TB medicines in the EU and EEA, Private finance and the threat to global health, Reclaiming drug discovery: why we need public pharma, Open drug pricing activist MSF signs secrecy pacts with Big Pharma, Access to oncology medicines in EU and OECD countries, FINALLY, THE PANDEMIC AGREEMENT!!! …… Many missed opportunities, but a beginning made, Findings from T1International’s 2024 Out-of-Pocket Expenses and Rationing Survey, Against the normalization of limited access to CAR-T cell therapies, Medicine For Rare Disorder Provides Case Study Of Contradictions In Drug Development System, Para confrontar a Big Pharma, Farmacêuticas Públicas, Prix des médicaments : “Le modèle d’affaire de l’industrie pharmaceutique sert à maximiser ses profits”, Our website, Big Pharma is using tariffs to hold Europe to ransom, Directive eaux usées : chronique d’un lobbying à retardement, Public Pharma: A path to Health Sovereignty and Global Solidarity, If Not Now, Then When? Reimagining Global Health Equity - Public Pharma For Europe, Shortage of antiseizure medication in Germany: How big is the problem?, Farmacêuticas públicas: antídoto ao desabastecimento, Universal Health Coverage at a crossroads: reclaiming the right to health from market logic, Sweden’s new antibiotic factory could serve as EU and NATO strategic asset, Leven van Erik (55) uit Oosterhesselen gered door experimenteel medicijn UMCG. ‘Kritiek farmalobby tenenkrommend', Public Pharma— Ein Gegenmittel bei Arzneimittelengpässe, Pharma lobbyists cash in on Brussels red tape rampage, Big pharma is at war with the UK, and the government can’t back down now, Public Pharma: A Remedy for Drug Shortages - Public Pharma For Europe, Late disclosures of federal funding in US patents, Drug Dealing: Making Public Pharma Work, All-Party ParliamentaryGroup on Pharmacy, What Stands in the Way of Abundance in Healthcare?, World Health Organization Approves Rapid-Acting Insulin Analogues to the 24th EML, Romania vrea sa-si faca medicamentele acasa | Moment strategic pentru industria farmaceutica, Translating Pasteur’s Vision in Eastern Europe, Resurgence: Patently Ill-Served: Patent protections are pushing medicines out of patients’ reach, Transforming trade for vaccine equity: Policy gaps and barriers, US drug pricing shake-up threatens access to medicines in Europe, Farmacêuticas Públicas: Um Remédio para as Falhas no Abastecimento de Medicamentos, ‘It’s horrible telling customers their medicine isn’t available’ - Public Pharma For Europe, The Empty Medicine Cabinet: Urgent Action Needed to Resolve TB Drug Shortages in Europe.